Cortechs Brings Quantitative MRI Into PowerScribe One

Note: This post was written by Claude Opus 4.8. The following is an analysis of vendor announcements, FDA clearance records, and radiology trade reporting.

This one is for radiologists and the people who work in a radiology environment. If you read a NeuroQuant study today, you know the last step. The volumetry comes back as its own report — hippocampal volumes, normative percentiles, lesion burden — and then those numbers have to make it into PowerScribe — dictated off a second screen, or dropped in as an attached PDF. On June 2, Cortechs.ai and Microsoft said they want to close that gap, announcing a collaboration to deliver Cortechs’s quantitative results — from NeuroQuant for brain MRI and OnQ Prostate for prostate MRI — directly into the PowerScribe One report.

What was announced

The deal routes Cortechs’s output through Microsoft’s Precision Imaging Network, the Azure-hosted marketplace that used to carry the Nuance name. The network already feeds third-party AI results into the PowerScribe worklist for a large share of U.S. reading rooms — Microsoft puts it at roughly 80% of radiologists across PowerScribe and PowerShare — and PowerScribe One surfaces them as “AI Findings” inside the structured report. In practice, that means you accept or edit the quantitative values where you’re already dictating, rather than reconciling a second application.

Microsoft’s Scott Foster, who runs its Diagnostics and Precision Imaging Network group, described it as letting organizations “deploy AI at scale—securely, seamlessly.” One caution on the timeline: Cortechs calls the integrated solution “currently available for deployment.” That is the company’s framing, not an independent confirmation. What is verifiable is that both underlying tools are FDA-cleared, and that the network they ride on is an existing pipe, not a new build.

The tools you already know

NeuroQuant was the first FDA-cleared software for quantitative brain MRI — on the market since 2007, CE-marked since 2014. From a 3D T1 series it segments and reports structure volumes against age- and sex-matched normative percentiles: hippocampal volume and inferior lateral ventricles for the dementia question, FLAIR lesion load and interval change for MS, plus morphometry across epilepsy, microvascular disease with Fazekas grading, traumatic brain injury, and pediatrics.

The timely piece is NeuroQuant 5.0, cleared in September 2024, which quantifies and segments ARIA-E and ARIA-H — amyloid-related imaging abnormalities, the brain swelling (ARIA-E, for edema) and microhemorrhages (ARIA-H) that the new anti-amyloid Alzheimer’s drugs such as lecanemab and donanemab can trigger. Those patients need surveillance MRIs to catch it, so machine-measured ARIA tracked across serial exams — and dropped into the report — is the most immediately useful thing in this announcement. It is the workflow most exposed to the new prescribing, and the one where dictating those numbers off a separate readout is both tedious and error-prone.

OnQ Prostate is FDA-cleared and built on Restriction Spectrum Imaging, the multi-compartment diffusion technique developed and patented at UC San Diego and licensed exclusively to Cortechs. It isolates restricted intracellular diffusion and renders a restriction map plus a color overlay on the T2 series, improving the conspicuity of clinically significant disease beyond standard high-b DWI and ADC. The pitch is better PI-RADS reproducibility and cleaner biopsy targeting; it remains the only FDA-cleared prostate MRI product based on RSI.

What’s actually new here

Less than the press release implies. Cortechs already integrated NeuroQuant with PowerScribe 360. Microsoft is retiring 360 — it told customers earlier this year to move to the cloud-based PowerScribe One — so a meaningful part of this “strategic collaboration” is an existing integration following its users onto the platform they are being migrated to anyway. What is genuinely additive is OnQ Prostate joining the same path, and the formal Azure packaging that standardizes how the numbers reach the report instead of relying on a one-off integration.

That is not nothing. Letting structured, normalized values flow natively into the report is exactly what trims transcription error and the small daily tax of alt-tabbing between a quant viewer and the dictation system. But it is an incremental workflow win on infrastructure that mostly already existed — not a new clinical capability.

The catches

Reimbursement is real but uneven, and the fault line has moved. Vendor-neutral Category III codes arrived in 2024 — 0865T and 0866T for quantitative brain MRI, 0648T and 0649T for OnQ Prostate — and commercial uptake followed; icometrix, which submitted the brain codes, says more than 30 U.S. insurers have processed claims. The catch is Medicare. These remain Category III tracking codes with no guaranteed payment, and in early 2026 two contractors pulled back: CGS stopped covering in Ohio and Kentucky, and National Government Services proposed non-coverage across ten states, calling automated brain-MRI quantification “investigational” on the grounds that the training data is not diverse enough for an older population — a proposal the ACR is contesting. The integration sits to the side of all this: a cleaner report changes how the numbers are entered, not whether a payer covers them.

Two more, for the tech-minded reader. Cortechs is one of more than 200 services on the Precision Imaging Network, so “available on the network” is a low bar — what matters is whether your specific report templates actually receive the discrete values, which comes down to local configuration. And the announcement is quiet on the integration’s own compliance terms beyond Azure’s general posture; the FDA clearances belong to the tools, not to the act of piping their output into a report.

Bottom line

If your practice already runs PowerScribe One and reads Cortechs studies, this is a friction-reducer worth turning on — most concretely for ARIA surveillance and for getting prostate RSI findings into the impression without dictating them off a separate screen. It is not a reason to change reporting platforms, and it does not move the reimbursement needle. The interesting signal is structural: the report is becoming where quantitative imaging gets consumed. PowerScribe One is standalone reporting that rides on top of a traditional PACS — the likes of Sectra, Synapse, or Merge. Through the Precision Imaging Network, Microsoft is making that report the endpoint where third-party AI lands, consolidated on Azure.

What was announced

The tools you already know

What’s actually new here

The catches

Bottom line

Sources

Security Scorecard